Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
2022studies shown
Showing 1,926-1,950 of 2,022
CompletedNCT01614912

Long-term Extension Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

This study exists to understand whether the medication SM-13496 is both safe enough and useful enough to take further. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 18 Years to 74 Years
Countries
Japan, Malaysia, South Korea, Taiwan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
CompletedNCT02335658

Long-term Study of DSP-5423P in Patients With Schizophrenia

This study exists to better understand the safety of the medication DSP-5423P and how manageable it feels in practice. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherOver 18 Years
Countries
Japan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
CompletedNCT01614899

A Phase III Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

This study exists to compare options and see whether the medication SM-13496 offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 18 Years to 74 Years
Countries
Japan, Malaysia, South Korea, Taiwan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
CompletedNCT04325737

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Japan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
CompletedNCT02287584

Confirmatory Study of DSP-5423P in Patients With Schizophrenia

This study exists to compare options and see whether the medication DSP-5423P offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherOver 18 Years
Countries
China, Japan, Malaysia, Philippines, Russian Federation, South Korea, Taiwan, Ukraine
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
CompletedNCT00711269

Study of SM-13496 (Lurasidone HCl) in Patients With Schizophrenia

This study exists to compare options and see whether the medication SM-13496 offers something meaningfully different. For people living with Schizophrenia, that matters because care needs to work in daily life, not just in theory.

SchizophreniaOtherFrom 18 Years to 74 Years
Countries
Japan, South Korea, Taiwan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
CompletedNCT03370640

Study Assessing the Safety, Tolerability, and Pharmacokinetics of SEP-363856 in Japanese Male and Female Subjects With Schizophrenia in 2 Parts (Part 1 and 2).

This study exists to better understand the safety of a medication treatment and how manageable it feels in practice. Researchers are trying to understand whether a medication treatment can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Japan
Sponsor
Sumitomo Pharma Co., Ltd.
Condition
Schizophrenia
TerminatedNCT03593213

Clinical Trial Evaluating the Efficacy, Safety, and Tolerability of Cariprazine in a Dose-Reduction Paradigm in the Prevention of Relapse in Participants With Schizophrenia

This study exists to compare options and see whether a medication treatment offers something meaningfully different. Researchers are trying to understand whether a medication treatment can better prevent setbacks and support longer-term stability.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Bulgaria, Malaysia, Poland, United States, Romania, Serbia, South Korea, Taiwan, Thailand, Ukraine
Sponsor
AbbVie
Condition
Schizophrenia
CompletedNCT01451736

Oral Risperidone Versus Injectable Paliperidone Palmitate for Treating First-Episode Schizophrenia

This study exists to compare options and see whether a guided support group offers something meaningfully different. Researchers are trying to understand whether a guided support group can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 45 Years
Countries
United States
Sponsor
University of California, Los Angeles
Condition
Schizophrenia
CompletedNCT03554655

The Efficacy of Using a Smartphone App to Support Shared Decision Making in People With a Diagnosis of Schizophrenia

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand whether a digital app or remote support tool can make support easier to access outside standard clinic visits.

SchizophreniaOtherFrom 18 Years to 35 Years
Countries
Denmark
Sponsor
Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital
Condition
Schizophrenia
CompletedNCT04310475

Virtual Reality Assisted CBT for Social Difficulties: a Feasibility Study in Early Intervention for Psychosis Services

This study exists to explore whether cognitive behavioural therapy, a structured talking treatment, could improve care and understanding. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United Kingdom
Sponsor
King's College London
Condition
Schizophrenia
TerminatedNCT03852706

EEG-based Neurofeedback for Auditory Verbal Hallucinations (HALFEED)

This study exists to see whether cognitive behavioural therapy, a structured talking treatment, is workable and worth testing more broadly. Researchers are trying to understand whether cognitive behavioural therapy, a structured talking treatment, can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherOver 18 Years
Countries
Ireland
Sponsor
University of Dublin, Trinity College
Condition
Schizophrenia
WithdrawnNCT04248010

Mechanistic Clinical Trial of Individualized tDCS for Hallucinations in Schizophrenia

This study exists to compare options and see whether the medication Individualized offers something meaningfully different. Researchers are trying to understand what the medication Individualized can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
Global
Sponsor
Columbia University
Condition
Schizophrenia
Not Yet RecruitingNCT04798131

fMRI-based Neurofeedback to Relieve Drug-resistant Auditory Hallucinations

This study exists to see whether a digital app or remote support tool can play a useful role in care. Researchers are trying to understand what a digital app or remote support tool can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
Global
Sponsor
University Hospital, Lille
Condition
Schizophrenia
CompletedNCT03870880

Study to Evaluate the Efficacy and Safety of Risperidone ISM® in Patients With Acute Schizophrenia: Open Label Extension

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can give earlier or clearer feedback during care.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
Ukraine, United States
Sponsor
Rovi Pharmaceuticals Laboratories
Condition
Schizophrenia
CompletedNCT00554840

Comparison of Varenicline and Placebo for Smoking Cessation in Schizophrenia

This study exists to see whether smoking support or smoking-related treatment is workable and worth testing more broadly. Researchers are trying to understand whether smoking support or smoking-related treatment can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Global
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT00161044

An Open-Label Investigation of the Adjuvant Therapeutic Effects of Galantamine in Patients With Chronic Schizophrenia and Persistent Deficit Symptoms

This study exists to explore whether a therapy or guided support program could improve care and understanding. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
WithdrawnNCT01584466

Long Acting Paliperidone in Dually Diagnosed People With Schizophrenia: An Open-label Pilot Study

This study exists to understand what helps a medication treatment work in everyday practice, not just under ideal conditions. Researchers are trying to understand whether a medication treatment can work better when mental health difficulties overlap with substance use.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT00176436

Atomoxetine for Treatment of Weight Gain in Olanzapine or Clozapine Patients

This study exists to explore whether a guided support group could improve care and understanding. Researchers are trying to understand what a guided support group could change in day-to-day care and decision-making.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT01182727

Salsalate for Insulin Resistance in Schizophrenia

This study exists to see whether a digital app or remote support tool is workable and worth testing more broadly. Researchers are trying to understand how people respond to a digital app or remote support tool in practice and what may need to be adjusted.

SchizophreniaOtherFrom 18 Years to 65 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia
CompletedNCT04783285

Effect of Individual Cognitive Stimulation at Home in Adults With Psychotic Disorders

This study exists to understand how a digital app or remote support tool holds up over time after the earliest research stage. Researchers are trying to understand whether a digital app or remote support tool can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 64 Years
Countries
Portugal
Sponsor
CEDIARA - Assoc. Solidariedade Social de Ribeira de Fráguas
Condition
Schizophrenia
CompletedNCT00708994

Cannabinoids, Neural Synchrony, and Information Processing

This study exists to explore whether brain scans or other body measurements could improve care and understanding. Researchers are trying to understand what brain scans or other body measurements can reveal about signals in the brain or body that may guide care later on.

SchizophreniaOtherFrom 18 Years to 55 Years
Countries
United States
Sponsor
Yale University
Condition
Schizophrenia
CompletedNCT01514682

Anti-Inflammatory Treatment of Schizophrenia

This study exists to see whether a therapy or guided support program can play a useful role in care. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

SchizophreniaOtherFrom 18 Years to 60 Years
Countries
United States
Sponsor
University of Maryland, Baltimore
Condition
Schizophrenia